A lecturer from the College of Education for Pure Sciences, at the University of Karbala, Dr. Ammar Abdul Hussein Al-Qarawi, obtained a patent from the Central Organization for Standardization and Quality Control to enable him to manufacture a new pharmaceutical compound.
The patent included the preparation of a medicinal derivative of benzoic maleimide, replaced with cephalexin. The new medicinal compound is characterized by antibacterial activity that exceeds the effectiveness of the original drug by several times, almost non-existent cellular toxicity, and a very high ability to inhibit the growth of cancer cells, with a concentration corresponding to the half-inhibition rate of (IC50 = 6.22) micrograms. \ml.
The patent aims to prepare a drug with dual biological activity to treat various infections, especially those that accompany cancerous diseases
